http://api.archives-ouvertes.fr/search/?fq=halId_s:hal-03860005&fl=title_s,en_title_s,docid,label_s,en_label_s,authIdHal_s,halId_s,structId_i,uri_s,keyword_s,en_keyword_s,authLastNameFirstName_s,journalTitle_s,abstract_s,en_abstract_s,producedDate_tdate,producedDateY_i,language_s&sort=publicationDate_s+desc
authors
- Bikfalvi Andreas
- da Costa Cristine Alves
- Avril Tony
- Barnier Jean-Vianney
- Bauchet Luc
- Brisson Lucie
- Cartron Pierre Francois
- Castel Hélène
- Chevet Eric
- Chneiweiss Hervé
- Clavreul Anne
- Constantin Bruno
- Coronas Valérie
- Daubon Thomas
- Dontenwill Monique
- Ducray François
- Enz-Werle Natacha
- Figarella-Branger Dominique
- Fournier Isabelle
- Frénel Jean-Sébastien
- Gabut Mathieu
- Galli Thierry
- Gavard Julie M
- Huberfeld Gilles
- Hugnot Jean-Philippe
- Idbaih Ahmed
- Junier Marie-Pierre
- Mathivet Thomas
- Menei Philippe
- Meyronet David
- Mirjolet Céline
- Morin Fabrice
- Mosser Jean
- Moyal Elisabeth Cohen-Jonathan
- Rousseau Véronique
- Salzet Michel
- Sanson Marc
- Seano Giorgio
- Tabouret Emeline
- Tchoghandjian Aurélie
- Turchi Laurent
- Vallette François M.
- Vats Somya
- Verreault Maïté
- Virolle Thierry
keywords
- Glioblastoma
- Invasion
- Resistance to therapy
- Tumor microenvironnement
- Glioblastoma
abstract
Glioblastoma (GBM) is the most deadly type of malignant brain tumor, despite extensive molecular analyses of GBM cells. In recent years, the tumor microenvironment (TME) has been recognized as an important player and therapeutic target in GBM. However, there is a need for a full and integrated understanding of the different cellular and molecular components involved in the GBM TME and their interactions for the development of more efficient therapies. In this review, we provide a comprehensive report of the GBM TME, which assembles the contributions of physicians and translational researchers working on brain tumor pathology and therapy in France. We propose a holistic view of the subject by delineating the specific features of the GBM TME at the cellular, molecular, and therapeutic levels.
more information